Grant ID DP220016
Awarded On February 16, 2022
Title CD4+CD26high CAR-T cells for the Treatment of Mesothelioma
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization Ares Immunotherapy, Inc.
Principal Investigator/Program Director Brian Newsom
Cancer Sites Lung and Bronchus
Contracted Amount $2,998,266*

*Pending contract negotiation

Lay Summary

Ares Immunotherapy Inc., an early-stage biopharma company founded in 2019, is located in Cartersville, Georgia with plans to move to Houston, Texas. In this SEED application, Ares is preparing for a first -in-human clinical trial in mesothelioma, a rare and deadly cancer most frequently associated with exposure to asbestos in the past. Ares' lead candidate, called Ares meso-CAR, is a mesothelin-specific chimeric antigen receptor (CAR) T cell therapy. CAR T-cell therapy is a form of immunotherapy that uses specially altered T cells - a part of the immune system - to fight cancer. In research studies, The Ares meso-CAR has been shown to be highly effective against solid tumors in cell studie...

Read More